Taponin, as a result of having been researched and developed by Shanghai Institute of Material Medical of the China Academy of Science and Zhejiang CONBA Pharmaceutical Company for five years, is a kind of product extracted from natural plant-----Ginkgo Leaves. The clinical trials, including 365 patients with obstructive coronary artery disease and angina pectoris show that Taponin’s total effective rate and significance effective rate are 92.8% and 70.1% respectively. The total effective rate for ischemic cardiogram change is 69.5%. The result of testing the blood samples of 76 patients with obstructive coronary artery disease shows Taponin can decrease blood viscosity, plasma peroxalipid(P—LPO) and serum triglycerin (S-TG), increase significantly the activity of erythrocyte superoxide dismutase (E-SOD) and the concentration of serum high density lipoprotein cholesterol (S-HDL-CH). There is no any side effect on the patients who have taken Taponin for long time. Above mentioned data are provided by the First Hospital of Zhejiang Medical University, Zhongshan Hospital of Shanghai Medical University and other twelve hospitals.
Capturing the free radical such as O2,OH and inhibiting the peroxidation of cell membrane
Preventing thrombosis and platelet aggregation.
Protecting and maintaining the function of myocardial ischemic heart in vivo and vitro.
Increasing the changeable ability of erythrocyte and decreasing blood viscosity.
Decreasing the formation of plasma peroxalipid and increasing the activity of erythrocyte superoxide dismutase.
Improving brain microcirculation and brain cell metabolism.
In short supply of coronary blood flow, angina pectoris myocardial ischemia, cerebral embolism and cerebrovascular spasm caused by arteriosclerosis and hypertension.
Administration and dosage:
Oral, two tablets each time, three times a day, or directed by physician.